Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Icotinib in Advanced NSCLC Post-Gefitinib
NCT01720901Phase 4Suspended
- Sponsor
- Betta Pharmaceuticals
- Start
- Feb 2013
- Primary completion
- Dec 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Feb 2013; status: suspended.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01720901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01720901.